Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.

Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, Gao LJ, Yang DH, Zhu DL

Journal of diabetes investigation16 Aug 2018Cited by 113 (Europe PMC)

PMID29957886PMCIDPMC6400178DOI10.1111/jdi.12888PepBankPUB-29957886

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study15

13 results from studies that gave the peptide. 13 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, liraglutide monotherapy reduced body weight.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide alone lowered body weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 29
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide and metformin reduced total, trunk, limb, android and gynoid fat mass; this also led to weight reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788601
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, liraglutide monotherapy reduced total fat mass.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide alone lowered total body fat.
Peptide
Liraglutide
Outcome
DecreaseTotal fat mass
Study
n = 29
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide and metformin reduced total, trunk, limb, android and gynoid fat mass; this also led to weight reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788602
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, liraglutide monotherapy reduced trunk fat mass.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide alone lowered fat on the trunk.
Peptide
Liraglutide
Outcome
DecreaseTrunk fat mass
Study
n = 29
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide and metformin reduced total, trunk, limb, android and gynoid fat mass; this also led to weight reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788603
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, liraglutide monotherapy reduced limb fat mass.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide alone lowered fat in the limbs.
Peptide
Liraglutide
Outcome
DecreaseLimb fat mass
Study
n = 29
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide and metformin reduced total, trunk, limb, android and gynoid fat mass; this also led to weight reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788604
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, liraglutide monotherapy reduced android fat mass.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide alone lowered fat around the abdomen.
Peptide
Liraglutide
Outcome
DecreaseAndroid fat mass
Study
n = 29
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide and metformin reduced total, trunk, limb, android and gynoid fat mass; this also led to weight reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788605
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, liraglutide monotherapy reduced gynoid fat mass.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide alone lowered fat around the hips.
Peptide
Liraglutide
Outcome
DecreaseGynoid fat mass
Study
n = 29
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide and metformin reduced total, trunk, limb, android and gynoid fat mass; this also led to weight reduction.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788606
07HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, blood glucose improved in the liraglutide arm, as in all treatment arms.
In plain wordsIn people with type 2 diabetes and fatty liver, blood glucose improved with liraglutide, as it did in the other treatment groups.
Peptide
Liraglutide
Outcome
DecreaseBlood glucose concentration
Study
n = 29
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Blood glucose concentrations and glycated hemoglobin levels improved in all treatment arms; levels of the latter were lower in patients treated with liraglutide and metformin.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788607
08HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, glycated hemoglobin improved in all arms, with lower levels in the liraglutide and metformin arms.
In plain wordsIn people with type 2 diabetes and fatty liver, glycated hemoglobin improved in all groups, with lower levels on liraglutide and metformin.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 29
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Blood glucose concentrations and glycated hemoglobin levels improved in all treatment arms; levels of the latter were lower in patients treated with liraglutide and metformin.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788608
09HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, serum alanine aminotransferase fell in the liraglutide arm, as in all arms.
In plain wordsIn people with type 2 diabetes and fatty liver, the liver enzyme ALT fell with liraglutide, as it did in all groups.
Peptide
Liraglutide
Outcome
DecreaseSerum alanine aminotransferase
Study
n = 29
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Serum alanine aminotransferase concentrations decreased in all treatment arms, whereas serum aspartate aminotransferase concentrations were reduced only by liraglutide and metformin.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788609
10HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, serum aspartate aminotransferase fell with liraglutide and metformin only.
In plain wordsIn people with type 2 diabetes and fatty liver, the liver enzyme AST fell with liraglutide and metformin but not with gliclazide.
Peptide
Liraglutide
Outcome
DecreaseSerum aspartate aminotransferase
Study
n = 29
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Serum alanine aminotransferase concentrations decreased in all treatment arms, whereas serum aspartate aminotransferase concentrations were reduced only by liraglutide and metformin.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788610
11HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, liraglutide monotherapy gave greater weight loss than gliclazide.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide led to more weight loss than gliclazide.
Peptide
Liraglutide
Outcome
DecreaseWeight loss versus gliclazide
Study
n: not reported in source
Comparator
Gliclazide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared with gliclazide, liraglutide and metformin monotherapies result in greater weight loss, reductions in body fat mass, and better blood glucose control among type 2 diabetes mellitus patients with non-alcoholic fatty liver disease.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788611
12HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, liraglutide monotherapy gave greater reductions in body fat mass than gliclazide.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide reduced body fat more than gliclazide.
Peptide
Liraglutide
Outcome
DecreaseFat mass reduction versus gliclazide
Study
n: not reported in source
Comparator
Gliclazide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared with gliclazide, liraglutide and metformin monotherapies result in greater weight loss, reductions in body fat mass, and better blood glucose control among type 2 diabetes mellitus patients with non-alcoholic fatty liver disease.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788612
13HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes and non-alcoholic fatty liver disease, liraglutide monotherapy gave better blood glucose control than gliclazide.
In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide controlled blood glucose better than gliclazide.
Peptide
Liraglutide
Outcome
DecreaseBlood glucose control versus gliclazide
Study
n: not reported in source
Comparator
Gliclazide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared with gliclazide, liraglutide and metformin monotherapies result in greater weight loss, reductions in body fat mass, and better blood glucose control among type 2 diabetes mellitus patients with non-alcoholic fatty liver disease.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
Report a problemFND-2995788613

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

14HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism
In all 85 patients pooled across the three drugs, reductions in weight and fat mass were positively correlated with decreases in serum ALT and AST.
In plain wordsAcross all patients on the three drugs, weight and fat loss went together with falls in liver enzymes.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of weight and fat mass reductions with ALT and AST decreases
Study
n = 85
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
In all patients, weight loss and total, trunk, limb, and android fat mass reductions were positively correlated with decreases in serum alanine aminotransferase and aspartate aminotransferase levels, whereas reductions in waist circumference were positively correlated with lower serum alanine aminotransferase levels.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2995788614
15HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism
In all patients pooled across the three drugs, reductions in waist circumference were positively correlated with lower serum alanine aminotransferase levels.
In plain wordsAcross all patients on the three drugs, a smaller waist went together with a lower level of the liver enzyme ALT.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of waist circumference reduction with ALT decrease
Study
n = 85
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
whereas reductions in waist circumference were positively correlated with lower serum alanine aminotransferase levels
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 85 patients were randomly allocated to receive gliclazide (n = 27), liraglutide (n = 29) or metformin (n = 29) monotherapy for 24 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2995788615

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.